No Prescription |
 |
 | ||
|
SIRDALUD Zanaflex |
|
| ||
No Prescription » Prescription Drugs 15 » SIRDALUD Zanaflex Tizanidine is used to relieve the spasms and increased muscle tone caused by multiple sclerosis (MS a disease in which the nerves do not function properly and patients may experience weakness numbness loss of muscle coordination and problems with vision speech and bladder control) stroke or brain or spinal injury. Tizanidine is in a class of medications called skeletal muscle relaxants. It works by slowing action in the brain and nervous system to allow the muscles to relax. Buy SIRDALUD Zanaflex and other Prescription Drugs 15 products online at Medstore. 572
About SIRDALUD Zanaflex: Product Type: Prescription Drugs 15 SIRDALUD ( Zanaflex Generic Tizanidine ) SIRDALUD (Zanaflex Generic Tizanidine) Zanaflex Generic Tizanidine 2mg Tabs 30 (5 x 6) Zanaflex Generic Tizanidine SIRDALUD
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
